Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment.

Cancer reports (Hoboken, N.J.) - 1 Feb 2026

Kai Yugo, Ikezawa Kenji, Kozumi Kazuhiro, Urabe Makiko, Takada Ryoji, Kinomoto Takumi, Masumoto Takanori, Kawabata Masaki, Kishimoto Hiroki, Hosokawa Kana, Mukai Kaori, Nakabori Tasuku, Yamaguchi Yuko, Sugimoto Naotoshi, Ohkawa Kazuyoshi

Abstract excerpt

BACKGROUND: Pembrolizumab is approved for treating patients with advanced solid tumors exhibiting high tumor mutation burden (TMB), including pancreatic cancer. However, owing to the rarity of TMB-high pancreatic cancer, its genetic and clinical characteristics, alongside the therapeutic effectiveness of pembrolizumab, remain unclear. AIMS: To investigate the characteristics and assess the effectiveness of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Immunological

Share to Biomarkers, Tumor

Share to Germ-Line Mutation

Share to Microsatellite Instability

Share to Pancreatic Neoplasms

Share to Smad4 Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 41668632
DOI: 10.1002/cnr2.70492
PMCID: PMC12892093

Genes

KRAS
BRCA2
CDKN2A
MLH1
MSH6
SMAD4
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment.PMID 41668632Read ↗

Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database.Semantic proximity Read ↗

Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor EffectivenessSemantic proximity Read ↗

Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board.Semantic proximity Read ↗

High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity.Semantic proximity Read ↗

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors.Semantic proximity Read ↗

Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.Semantic proximity Read ↗

Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical PracticeSemantic proximity Read ↗

Molecular and Clinical Features of Pancreatic Acinar Cell Carcinoma: A Single Institution Case SeriesSemantic proximity Read ↗

Molecular testing for personalized therapy is underutilized in patients with borderline resectable and locally advanced pancreatic cancer - real world data from the NORPACT-2 study.Semantic proximity Read ↗

Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomesSemantic proximity Read ↗

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.Semantic proximity Read ↗

Hypermutation In Pancreatic Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.